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Pseu do hy popar ath yroi dism (PHP) and related dis-
orders are associated with a spectrum of abnormal 
physical characteristics as well as neurocognitive and 
endocrine abnormalities that are caused primarily by 
molecular defects that impair hormonal signalling via 
receptors that are coupled, through the α- subunit of the 
stimulatory G protein (Gsα), to activation of adenylyl 
cyclase (Fig. 1).
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Abstract | This Consensus Statement covers recommendations for the diagnosis and management 
of patients with pseu do hy popar ath yroi dism (PHP) and related disorders, which comprise 
metabolic disorders characterized by physical findings that variably include short bones, short 
stature, a stocky build, early- onset obesity and ectopic ossifications, as well as endocrine defects 
that often include resistance to parathyroid hormone (PTH) and TSH. The presentation and 
severity of PHP and its related disorders vary between affected individuals with considerable 
clinical and molecular overlap between the different types. A specific diagnosis is often delayed 
owing to lack of recognition of the syndrome and associated features. The participants in this 
Consensus Statement agreed that the diagnosis of PHP should be based on major criteria, 
including resistance to PTH, ectopic ossifications, brachydactyly and early- onset obesity. The 
clinical and laboratory diagnosis should be confirmed by a molecular genetic analysis. Patients 
should be screened at diagnosis and during follow- up for specific features, such as PTH resistance, 
TSH resistance, growth hormone deficiency , hypogonadism, skeletal deformities, oral health, 
weight gain, glucose intolerance or type 2 diabetes mellitus, and hypertension, as well as 
subcutaneous and/or deeper ectopic ossifications and neurocognitive impairment. Overall, a 
coordinated and multidisciplinary approach from infancy through adulthood, including a 
transition programme, should help us to improve the care of patients affected by these disorders.
*e- mail: gnanclares@
osakidetza.eus;  
agnes.linglart@aphp.fr
https://doi.org/10.1038/ 
s41574-018-0042-0
476 | AUGUST 2018 | volUme 14 
CONSENSUS
Statement
www.nature.com/nrendo
© 2018 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.
The term PHP (Online Mendelian Inheritance in 
Man (OMIM) #103580 for PHP type 1A (PHP1A), 
#603233 for PHP type 1B (PHP1B) and #612462 for 
PHP type 1C (PHP1C)) describes disorders that share 
common biochemical features of hypoparathyroidism 
(that is, hypocalcaemia and hyperphosphataemia) 
that are the result of resistance of target tissues to the 
biological actions of parathyroid hormone (PTH). In 
some cases, resistance to other hormones (such as TSH, 
gonadotropins, growth hormone- releasing hormone 
(GHRH) and calcitonin) that have receptors coupled 
via Gsα is observed. Patients with PHP1A and PHP1C 
are also characterized by the variable expression of a col-
lection of physical features, termed Albright hereditary 
osteodystrophy (AHO), which includes premature clo-
sure of growth plates and short bones, short stature, a 
stocky build, ectopic ossifications and other poorly 
defined abnormalities. In some patients, the physical 
features of AHO might be present in the absence of hor-
mone resistance. Furthermore, based on the number of 
AHO features and the extent of ectopic ossifications, 
patients might be classified as having pseudopseu do hy-
popar ath yroi dism (PPHP; OMIM #612463), progressive 
osseous heteroplasia (POH; OMIM #166350) or osteoma 
cutis. PHP and PPHP were initially described by Fuller 
Albright and colleagues in 1942 (reF.1) and 1952 (reF.2), 
respectively; POH was reported more than five decades 
later, in 1994 (reF.3). Other features have been attributed 
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to these disorders since their identification, such as intra-
uterine growth failure, early-onset obesity (that is, devel-
opment in the first few months of life and full expression 
before the end of infancy), hypogonadism, growth 
hormone (GH) deficiency and cognitive impairment, 
including developmental delay and loss of intellectual 
function4. Acrodysostosis (OMIM #101800) refers to 
a group of chondrodysplasias that resemble PHP in 
some patients, owing to the presence of brachydactyly 
and often resistance to PTH and TSH, but differ from 
PHP owing to more extensive facial dysmorphism, nasal 
hypoplasia and often developmental delay5,6.
The exact prevalence of PHP is unknown. Studies 
published in 2000 and 2016 estimated the prevalence 
to be 0.34 in 100,000 in Japan7 and 1.1 in 100,000 in 
Denmark8. A limitation of both studies is that the inves-
tigators did not confirm the clinical diagnosis of PHP by 
a molecular analysis for the majority of the patients. The 
prevalence of POH has never been estimated. However, 
it seems to be extremely rare, as <60 cases have been 
reported worldwide up to December 2016 (reFs9,10). The 
overlap between PPHP and PHP1A means that determin-
ing the prevalence of PPHP is even more complicated. 
Acrodysostosis is uncommon; the prevalence of the 
disease is unknown, and clinical, biochemical and 
radiological features overlap with those of PHP1A 
and PPHP6,11–15.
A molecular cause can be identified in an estimated 
80–90% of patients with PHP or related disorders16,17. 
The most common underlying mechanisms are de novo 
or autosomal dominantly inherited genetic mutations 
and/or epigenetic, sporadic or genetic-based alterations, 
within or upstream of GNAS4,18,19, PRKAR1A6, PDE4D5,20 
or PDE3A21 (Fig. 1; Supplementary Table 1).
In the absence of molecular analysis, the clinical and 
biochemical overlap between PHP and related disorders 
can lead to challenges in diagnostic classification and 
thus in understanding the natural history of the different 
types. A consensus meeting was organized to develop 
recommendations for the diagnosis and management of 
patients with PHP and related disorders.
The European Cooperation in Science and Techno-
logy (COST) action BM1208 (European Network for 
Human Congenital Imprinting Disorders, see Related 
links), the European Reference Network on Rare 
Endocrine Conditions (ENDO-ERN), the European 
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Fig. 1 | Molecular defects in the PTH–PTHrP signalling pathway in PHP 
and related disorders. Upon ligand binding (parathyroid hormone (PTH) 
and parathyroid hormone- related protein (PTHrP) are shown on the figure), 
the G protein coupled PTH/PTHrP receptor type 1 (PTHR1) activates the 
heterotrimeric Gs protein. The Gsα subunit triggers the activation of 
adenylyl cyclase, which leads to cAMP synthesis. cAMP then binds to the 
regulatory 1 A subunits (R) of protein kinase A (PKA), the predominant 
effector of cAMP. Upon cAMP binding, the catalytic subunits (C) dissociate 
from the R subunits and phosphorylate numerous target proteins, including 
cAMP- responsive binding elements (CREB) and the phosphodiesterases 
(PDEs; such as PDE3A and PDE4D). CREB activates the transcription 
of cAMP-responsive genes. Intracellular cAMP is then deactivated 
by PDEs, including PDE4D and PDE3A. The main clinical features of 
pseu do hy pop ar ath yroi dism (PHP) and related disorders are due to 
molecular defects within the PTH–PTHrP signalling pathway , with the 
exception, perhaps, of ectopic ossification. The diseases caused by 
alterations in the genes that encode the indicated proteins are shown in 
blue boxes. Differential diagnoses are shown in grey boxes. CRE, cAMP 
response element; HDAC4, histone deacetylase 4; G protein, trimer α, β and γ; 
HTNB, autosomal dominant hypertension and brachydactyly type E 
syndrome; PHP, pseu do hy popar ath yroi dism; PHP1A , pseu do hy popar ath-
yroi dism type 1A ; PHP1B, pseu do hy popar ath yroi dism type 1B; PHP1C, 
pseu do hy popar ath yroi dism type 1C; POH, progressive osseous 
heteroplasia; PPHP, pseudopseu do hy popar ath yroi dism; PTHLH, 
parathyroid hormone- like hormone; TF, transcription factor ; TRPS1, 
zinc- finger transcription factor TRPS1.
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Reference Network on Rare Bone Disorders (BOND- 
ERN), the European Calcified Tissue Society (ECTS), the 
Asian Pacific Paediatric Endocrine Society (APPES), 
the European Society of Human Genetics (ESHG), the 
Pediatric Endocrine Society (PES), the European 
Society of Endocrinology (ESE) and the European Soci-
ety for Paediatric Endocrinology (ESPE) support this 
Consensus Statement.
Methods
Thirty- seven participants from 13 countries were 
invited to participate in the development of this 
Consensus Statement based on their publication record 
and expertise in PHP and related disorders, and seven 
representatives from patient support groups from four 
countries were also included. Health- care profession-
als included endocrinologists, paediatric endocrinolo-
gists, paediatric nephrologists, a neonatologist, dentists, 
molecular biologists, molecular geneticists and a project 
coordinator/manager. Representatives from patient sup-
port groups (Spanish Association of Pseudohypopara- 
thyroidism (AEPHP), K20, the acrodysostosis group and 
the Italian Association of POH (IPOHA)) participated 
in all the discussions but did not vote for the final rec-
ommendations. Experts included representatives nom-
inated by the council and clinical practice committees 
from six international societies, two European reference 
networks and a European network on imprinting disor-
ders (COST BM1208). All participants signed a conflict 
of interest declaration, and the consensus was strictly 
supported by funding from academic or professional 
societies only, with no sponsorship from the pharma-
ceutical industry. A Delphi-like consensus methodology 
was adopted22.
A comprehensive literature search was conducted 
using PubMed including articles published from 
1 January 1990 through 18 December 2016. The 
search terms used were “pseu do hy popar ath yroi dism 
or PHP”, “Albright’s Hereditary Osteodystrophy 
or AHO”, “pseudopseu do hy popar ath yroi dism or 
PPHP”, “progressive osseous heteroplasia or POH”, 
“acrodysostosis”, “osteoma cutis”, “ectopic ossifica- 
tions”, “subcutaneous ossifications”, “PTH resistance”, 
“brachydactyly”, “Fahr syndrome”, “calcaemia” and 
“hypocalcaemia”. The search was restricted to patients 
with a genetic diagnosis, so the following search terms 
were also included: “GNAS or GNAS1 or Gs- alpha”, 
“PRKAR1A”, “PDE4D”, “PDE3A”, “PTH1R or PTHR1”, 
“HOXD13”, “HDAC4”, “TRPS1”, “PTHLH”, “multi-
locus hypomethylation or multilocus methylation 
defect or multilocus imprinting disturbance or MLID” 
and “prenatal testing and imprinting”. The year 1990 
was chosen as a cut- off as it was the year in which the 
first inactivating GNAS mutations associated with 
PHP were described. Only publications in English 
were considered. Additional relevant articles on ini- 
tial clinical descriptions, differential diagnoses and 
treatments were also identified by PubMed searches 
when supplementary information was necessary. 
A comprehensive review of >800 articles formed the 
basis of discussion by three working groups (WGs). 
These groups focused on clinical diagnosis (WG1: 
A.L., Su.T., S.F.A., G.D.F., L.G., H.J., E.L.N., M.A.L., 
O.M., P.M., L.R., R.R., A.H.S., Se.T., P.W. and M.C.Z.), 
molecular diagnosis (WG2: G.P.d.N., M.B., D.M., T.E., 
F.M.E., K.F., P.H., M.-L.K., A.P., E.M.S. and C.S.) and 
clinical management (WG3: G.M., R.B., T.C., L.d.S., 
G.D., A.G.R., E.L.G.-L., N.H., O.H., P.K., N.K., B.L., 
R.M., G.A.M.-M., M.M., R.P., A.R., V.S. and A.U.).
Preparation for the consensus took >24 months, 
including two preparatory meetings. A preliminary 
document summarizing the questions addressed in the 
preparatory meetings was prepared by each WG and 
shared for review with all the experts before the final 
consensus meeting. At the final consensus meeting, 
propositions and recommendations were considered by 
participants and discussed in plenary sessions, enabling 
reformulation of the recommendations, if necessary. 
Where published data were unavailable or insufficient, 
experts’ clinical experiences and opinions were consid-
ered. Therefore, this Consensus Statement focuses on 
disorders for which we have sufficient published data 
and/or expertise, including PHP1A, PHP1B, PHP1C, 
PPHP, POH and acrodysostosis. All experts voted on 
the recommendations proposed by each working group 
using the following system: A. evidence or general 
agreement allows full agreement with the recommen-
dation; B. evidence or general agreement is in favour of 
the recommendation; C. evidence or general agreement 
is weak for the recommendation; D. there is not enough 
evidence or general agreement to agree with the recom-
mendation. If there was a majority of D, the recommen-
dation was not accepted. Depending on the proportion 
of votes received by the option with the most votes, the 
strength of the recommendation was recorded as fol-
lows: + (26–49% of the votes), ++ (50–69% of the votes) 
and +++ ( ≥70% of the votes).
Clinical diagnosis
PHP and related disorders vary considerably in clinical 
presentation and disease severity between affected indi-
viduals, even among patients carrying the same genetic 
alteration. The clinical symptoms (for instance, ossifi-
cations and brachydactyly) and abnormalities that can 
be detected in a laboratory (for instance, hypocalcaemia 
and raised levels of PTH) (Table 1) typically worsen dur-
ing mid and late childhood and are usually unnoticed 
in very young children. A correct diagnosis can thus 
be elusive during infancy and in patients with atypical 
features23.
Clinical definitions
Albright hereditary osteodystrophy. The term AHO is 
used to indicate a constellation of physical features orig-
inally described by Albright1, including a round face, a 
stocky habitus with short stature, brachydactyly and 
ectopic ossification. Short bones are not present at birth 
and result from premature closure of the epiphyses, lead-
ing to a reduced period of growth. Although all bones tend 
to be short, shortening is most marked acrally (that is, in 
the hands and feet). Subsequently, developmental delay 
was added as an additional feature of AHO24,25. Obesity, 
particularly early- onset obesity, and macrocephaly relative 
to height might be part of AHO26–28.
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Pseu do hy popar ath yroi dism. The demonstration that lev-
els of Gsα, the α- subunit of the heterotrimeric G protein 
that couples heptahelical receptors to activation of adenylyl 
cyclase, were reduced in erythrocytes from some patients 
with PHP led to the first subclassification within PHP29.
PHP1A was initially defined as the association of 
resistance to multiple hormones, including PTH and 
TSH, features of AHO and decreased Gsα activity using 
in vitro assays29. Evidence of TSH resistance is often pres-
ent at birth and can lead to the misdiagnosis of congeni-
tal hypothyroidism24,30, whereas PTH resistance develops 
during childhood31–34. Similarly, brachydactyly devel-
ops progressively and usually becomes obvious before 
puberty34,35. Additional features have been described in 
patients with PHP1A. For instance, affected patients are 
born with a moderately reduced birth length that usually 
does not prompt investigations24,30,36–38. Obesity might 
develop in very early life and be recognized before any 
endocrine disturbances appear in early childhood30,35,39. 
The presence of extensive or progressive ossifications 
that extend deep into connective tissues is unusual but 
does not preclude the diagnosis of PHP1A40,41. Cognitive 
impairment has been associated with the diagnosis of 
PHP1A; when present, the severity of impairment is 
highly variable24,42. However, about 30% of patients with 
PHP1A present with normal cognitive development24.
PHP1C has been defined as the association of all the 
features of PHP1A but with documentation of normal 
Gsα activity in in vitro complementation assays that 
do not assess the ability of receptors to activate the Gs 
heterotrimer43. As a result of the overlap with PHP1A and 
of the lack of assessment of Gsα activity in most reports 
(and thus the lack of distinction between PHP1A and 
PHP1C), we have not specifically addressed PHP1C. This 
form is considered to be a variant of PHP1A in the text 
and the recommendations unless otherwise specified.
PHP1B was initially defined as isolated resistance to 
PTH, absence of AHO and normal levels of Gsα activity. 
Subsequent analyses have demonstrated that some 
patients with PHP1B display additional features that over-
lap with PHP1A. As in PHP1A, PTH resistance might not 
be present at birth and develops only over time44–50. TSH 
resistance and patterns of excessive intrauterine growth or 
weight gain at birth or during early infancy and childhood 
have been described44,51,52. Some patients with PHP1B 
present with one or several features of AHO, the most 
frequent being brachydactyly51,53. Subcutaneous ossifica-
tions are very uncommon51,53,54. Owing to the overlap of 
some AHO features, distinguishing between PHP1A and 
PHP1B can be difficult in some patients; even more so as, 
although rarely investigated, mildly decreased Gsα activity 
has also been described in some patients with PHP1B55.
PHP type 2 (PHP2) is characterized by an increase in 
levels of cAMP in response to exogenous PTH infusion 
but a deficient phosphaturic response56. The exact molec-
ular cause of this disease variant is still unknown, but it 
has been suspected that PHP2 could either be an acquired 
defect secondary to vitamin D deficiency57 or be due to 
defective signalling downstream of Gsα, as in patients 
with acrodysostosis due to PRKAR1A mutations6.
Pseudopseu do hy popar ath yroi dism. PPHP is defined 
as AHO, with decreased Gsα activity, in the absence of 
PTH resistance. Birthweight and length restriction are 
frequent36. Subcutaneous ossifications are also frequent 
(osteoma cutis and bony plaques)58,59 and highly sugges-
tive of Gsα deficiency. In some cases, mild resistance to 
PTH and TSH might occur60.
Table 1 | Main clinical features of PHP and related disorders
Feature PHP1A PHP1B PPHP POH ACRDYS1 ACRDYS2
Growth • Growth velocity 
decreasing 
progressively
• Adult short stature
• Macrosomia
• Average adult 
stature
• SGA
• Growth velocity 
decreasing 
progressively
• Adult short stature
SGA • SGA
• Adult short stature
• SGA
• Adult short 
stature
Obesity Early  onset Early onset Normal weight or 
lean
Normal weight 
or lean
Present Present
Brachydactyly 70–80% 15–33%  <30% Rare 97% 92%
Advanced bone age 70–80% 15–33% Unknown Unknown 100% 100%
Ectopic ossification 30–60% 0–40% 18–100% 100% 0% 0%
PTH resistance 
(progressive)
100% 100% Rare and mild Absent 100% 29%
TSH resistance 100% 30–100% Rare and mild Absent ~100% 16%
Neurological 
symptoms
• Neurocognitive 
impairment
• Cerebral calcifications
Cerebral 
calcifications
Unknown Unknown Unknown Neurocognitive 
impairment
Gonads Gonadotropin 
resistance
Normal Normal Unknown Case reports of 
anatomical dysfunction
Unknown
Pseu do hy popar ath yroi dism (PHP) and related disorders affect many organs unequally. The clinical and biochemical features of the main diseases have been 
represented with their frequency when known. ACRDYS1, acrodysostosis due to mutation in PRKAR1A; ACRDYS2, acrodysostosis due to mutation in PDE4D; 
PHP1A , pseu do hy popar ath yroi dism type 1A due to maternal loss of function mutation at the GNAS coding sequence; PHP1B, pseu do hy popar ath yroi dism type 1B 
due to methylation defect at the GNAS coding sequence; POH, progressive osseous heteroplasia (due to paternal loss- of-function mutation at the GNAS coding 
sequence); PPHP, pseudopseu do hy popar ath yroi dism (due to paternal loss of function mutation at the GNAS coding sequence); PTH, parathyroid hormone; SGA , 
small for gestational age.
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Progressive osseous heteroplasia. POH is defined by the 
presence of ectopic ossifications that are progressive and 
extend deep into connective tissue. At least one bony 
plate is present. Patients with POH usually have no 
other features of AHO and have normal responsiveness 
to PTH. The ossifications might lead to severe ankyloses 
of affected joints and focal growth retardation. Several 
clinical and genetic features can be suggestive of the diag-
nosis, such as a mutation involving exons 1–13 of the 
paternal GNAS allele, radiographic evidence of a reticular 
pattern of ossification, histological evidence of exclusive 
intramembraneous ossification or both intramembrane-
ous and endochondral ossification, lateralization of the 
ossifications in a dermomyotomal pattern, being born 
small for gestational age (SGA), leanness and onset of 
ossifications before 1 year of age10. POH- like features 
have also been described in several patients in whom the 
GNAS mutations were located on the maternal allele41.
Acrodysostosis. Acrodysostosis is defined as the asso-
ciation of severe brachydactyly, facial dysostosis and 
nasal hypoplasia. Brachydactyly usually affects all pha-
lanxes, metacarpals and metatarsals except for thumbs 
and halluces. On radiographs, epiphyses display a cone 
shape, bone age is advanced and abnormalities might 
be present at birth or soon thereafter. In some cases, the 
chondrodysplasia is indistinct from that of AHO11–13,15,61. 
Other symptoms might also be present in patients with 
acrodysostosis, such as cognitive impairment15,62, being 
born SGA and resistance to PTH and/or other hormones 
that signal through Gsα6,13,15,63,64.
Effect of correct diagnosis. Confirmation of the diagnosis 
is important for patients and for parents of children with 
PHP and related disorders, as this guides appropriate 
management and prevents further, sometimes exten-
sive, investigation of frequent presenting signs, such as 
growth failure, obesity and/or seizures, to identify the 
underlying cause. Conversely, exclusion of the diagnosis 
will prompt further investigation and consideration of 
alternative underlying conditions.
Establishing the correct diagnosis in patients with 
PHP, PPHP, POH or acrodysostosis allows an appropri-
ate conversation to take place with patients and families, 
including anticipatory guidance, and informs decisions 
on biochemical screening and treatment of potential 
endocrine defects. Families can be directed to appropriate 
support groups, and genetic counselling can be offered. 
Identifying patients with these disorders is also important 
to allow further research into the underlying incidence, 
natural history and aetiology of the disease phenotypes.
Recommendations
1.1.  The diagnosis of PHP and related disorders should 
be based on clinical and biochemical characteristics, 
which will vary depending on the age of the patient 
and, in some cases, on the family history (A+++).
1.2.  In the context of PHP and related disorders, the 
diagnosis of AHO should be based on the presence 
of the following clinical features:
•	 Major criterion: brachydactyly type E (premature 
fusion of the epiphyses)
•	 Major criterion: short stature by adulthood relative 
to the height of the unaffected parent
•	 Additional criterion: stocky build
•	 Additional criterion: round face in comparison 
with siblings and degree of obesity, if present
•	 Additional criterion: ectopic (and often subcutaneous) 
ossifications
 All features might not be present and might evolve 
throughout the observation period. Obesity, SGA, 
dental manifestations and cognitive impairment are 
present only in a subgroup of patients; these features 
are not required for the diagnosis of AHO (A++).
1.3.  Clinical and biochemical major criteria for PHP and 
related disorders are as follows (A+++):
•	 PTH resistance
•	 And/or subcutaneous ossifications that can 
include deeper ossifications
•	 And/or early- onset (before 2 years of age) obesity 
associated with TSH resistance or with one of the 
above
•	 And/or AHO alone
•	 With or without a family history
1.4.  The following features support the diagnosis of PHP 
and related disorders (A+++):
•	 Endocrine: elevated levels of TSH, unexplained 
congenital hypothyroidism (mildly elevated lev-
els of TSH), hypogonadism, hypercalcitoninaemia 
and/or GH deficiency
•	 Neurological: cognitive impairment, hearing 
impairment, spinal stenosis, Chiari malformation 
type 1, syringomyelia, carpal tunnel syndrome 
and/or craniosynostosis
•	 Mineralization defects: enamel hypoplasia, delayed 
tooth eruption or tooth ankylosis, oligodontia or 
hypodontia, advanced skeletal maturation, cataract 
and/or central nervous system (CNS) calcifications
•	 Others: sleep apnoea, ear infection, asthma, 
early- onset obesity, SGA and/or cryptorchidism
1.5.  PHP and related disorders are primarily clinical diag-
noses. Identification of the molecular cause should 
be performed to confirm the clinical diagnosis and 
allow the characterization of the subtype of the 
disease (A++).
1.6.  Testing for genetic or epigenetic causes should be 
based on the clinical characteristics, local access to 
genetic testing and the most likely identified causes 
of the disease at the time of analysis according to the 
algorithm (see Molecular diagnosis section) (A++).
 The experts have highlighted that administration 
of exogenous PTH (modified Ellsworth–Howard 
test) is not necessary but might be helpful in 
research settings. Assessment of Gsα bioactivity is 
usually not required for the clinical diagnosis of 
PHP and related disorders.
Main clinical components
In the majority of patients with PHP, the most impor-
tant clinical manifestation is symptoms of hypocalcae-
mia due to PTH resistance (45–80%)65. Periods of rapid 
growth and the associated increased calcium require-
ment, or nutritional calcium or vitamin D deficiency, 
might trigger or intensify symptoms34.
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Resistance to PTH. In patients with PHP1A, resistance 
to PTH is usually absent at birth and evolves over life 
(from 0.2 years to 22 years)18,31,34, while the clinical 
manifestations typically occur later. These data sug-
gest that PTH resistance begins in early childhood, 
and the resultant changes in serum levels of calcium and 
phosphorus develop gradually, at some point during 
adulthood31,32,66–68. The first biochemical abnormalities 
to become apparent are elevated serum levels of PTH 
and elevated serum levels of phosphorus, followed by 
hypocalcaemia. When hypocalcaemia is present, urine 
levels of calcium are low, whereas calcitriol levels might 
be either low or normal18. An interval of up to 4.5 years 
usually occurs between the start of the elevation in levels 
of PTH and phosphorus and onset of hypocalcaemia67.
Patients with PHP1B might show variable degrees 
of PTH- resistant hypocalcaemia or normocalcaemia, 
despite identical epigenetic changes involving tran-
scription start site (TSS)–differentially methylated 
region (DMR) at exon A/B of GNAS (GNAS A/B:TSS- 
DMR)47,66,69,70. Long- standing secondary hyperpara-
thyroidism with chronic hypocalcaemia and calcitriol 
deficiency has been associated with tertiary hyperpar-
athyroidism in these patients71. Chronically elevated 
levels of PTH might also lead to bone resorption and 
demineralization that resemble the bone changes seen 
in rickets in children with irregular and widened met-
aphyses, Madelung- like deformity or primary hyper-
parathyroidism, including brown tumours (a bone 
lesion that can occur when osteoclast activity due to 
hyperparathyroidism is excessive)72.
Resistance to PTH is also present in patients with muta-
tions in PRKAR1A5,6,15,20,63,64; however, hypocalcaemia has 
not been documented in these patients yet. Patients with 
PDE4D mutations usually display normal levels of PTH, 
except in the context of calcifediol deficiency5,13–15,20,62,63.
Recommendations
1.7.  The definition of PTH resistance is as follows:
•	 The association of hypocalcaemia, hyperphos-
phataemia and elevated serum levels of PTH in 
the absence of vitamin D deficiency and when 
magnesium levels and renal function are normal.
•	 PTH resistance in the context of PHP and related 
disorders should be suspected when PTH is at, or 
above, the upper limit of normal, in the presence 
of normal calcifediol levels and elevated serum 
levels of phosphorus, even in the absence of overt 
hypocalcaemia.
 PTH resistance and consequent changes in serum lev-
els of calcium, phosphorus and PTH can be variable, 
and repeated testing might be required (A+++).
Ectopic ossification. Disorders caused by molecular 
alterations of the GNAS gene or locus, such as PHP1A, 
PHP1C, PPHP and POH, can feature ectopic ossification. 
Ectopic ossification is not calcification and is unrelated to 
serum levels of calcium and phosphorus. The ectopic ossi-
fications are a manifestation of Gsα deficiency in mesen-
chymal stem cells, with de novo formation of extraskeletal 
osteoblasts that form islands of ectopic bone in the dermis 
and the subcutaneous fat as a result of the differentiation 
of adipose- derived progenitor mesenchymal stem cells 
that lead to predominantly web- like intramembranous 
ossifications73,74. Unlike fibrodysplasia ossificans progres-
siva (FOP), where injury, viral infections and immuniza-
tions can lead to ossifications, no formal evidence exists 
to suggest that the same events lead to ectopic bone for-
mation in GNAS- based conditions. Ectopic ossifications 
are found in 100%, 80–100%, 30–60% and very uncom-
monly in patients with POH, PPHP or AHO, PHP1A 
and PHP1B, respectively, and have never been reported 
in patients with acrodysostosis13,61,75–78.
Osteoma cutis (a form of ectopic ossification) is 
usually present at birth or develops very early in life, 
more rarely during childhood and adulthood, as a single 
large plaque in the skin, as an isolated dermal nodule or 
nodules or as multiple papules on the face79. Osteoma 
cutis is associated with normal serum levels of calcium 
and phosphorus throughout life, which suggests that 
the mutation is on the paternal GNAS allele41,58,59,80–82. 
Ossifications that develop in patients with POH are 
progressive and extend into the muscles, tendons and 
ligaments10,41,83. The ossifications in patients with POH 
can be limited to or be much more prominent on one 
side of the body, which suggests that the mechanism of 
the disease encompasses a second mutational mosaic hit 
or variations in GNAS imprinting or Gsα expression84.
Recommendations
1.8.   Ectopic ossifications should be considered as a 
specific sign of GNAS mutations (specifically when 
observed at birth or in early childhood) (A++).
1.9.   The description of the ossifications, their location 
and their extension in connective tissues should 
be considered to establish the diagnosis of POH 
versus osteoma cutis, PHP1A, PHP1C, PPHP or 
AHO, where the latter conditions have ectopic 
bone that remains superficial (B++).
1.10.  The diagnosis of osteoma cutis, nodules of subcuta-
neous ossifications or deep heterotopic ossifications 
should trigger a clinical and biochemical work- up 
to search for signs of AHO, PTH and TSH resist-
ance or FOP, especially if the first digit of both feet is 
abnormal. If the diagnosis is obvious or very likely, a 
biopsy sample is not needed and is contraindicated 
in case of suspicion of FOP (A+++).
Brachydactyly. In PHP and related disorders, brachy-
dactyly can be classified as type E, which is defined as 
variable shortening of the metacarpals with, usually, 
normal length of phalanges, occasionally accompanied 
by relatively shortened metatarsals. In PHP and related 
disorders, the fifth, fourth and third metacarpal and the 
first and fourth distal phalanges are the most affected 
bones of the hand85; metatarsals are often shortened as 
well. Brachydactyly develops over time and might not be 
evident in early life, except in patients with acrodysos-
tosis6,35,86. The frequency and severity of brachydactyly 
vary among the different disorders: 70–80% in PHP1A51, 
15–33% in PHP1B46,51,70,87–93 and all patients with acrodys-
ostosis5,6,14,15,20,62–64,94–96 (Table 1). However, brachydactyly is 
not specific to PHP and related disorders and can be found 
in patients with, for example, tricho–rhino–phalangeal 
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syndrome, brachydactyly mental retardation syndrome 
or Turner syndrome (Table 2).
Recommendations
1.11.  When brachydactyly type E is identified, other 
disorders associated with bone dysplasia should be 
excluded, for example, Turner syndrome, tricho–
rhino–phalangeal syndrome, isolated brachydac-
tyly type E and brachydactyly mental retardation 
syndrome (A+++).
1.12.  If not present in infancy, brachydactyly type E 
should be searched for (clinically and radiologi-
cally) from early childhood onwards in all patients 
with PHP and related disorders (A+++).
TSH resistance
Patients with PHP1A frequently (if not always97) present 
with raised serum levels of TSH and thyroid hormone 
levels that are normal or slightly reduced. Some patients 
present with overt clinical hypothyroidism. Elevated 
levels of TSH due to TSH resistance might be present at 
birth and detected on neonatal screening24,30,31,60,67,98–100. 
In PHP1B, TSH levels are at the high end of normal 
or mildly elevated in 30–100% of patients47,87,89,92,101–105. 
TSH resistance is present in patients with acrodysos-
tosis owing to PRKAR1A mutations but not in those 
with PDE4D mutations13,15. Thyroid autoantibodies 
are usually absent in patients with PHP1A, PHP1B 
or acrodysostosis who have elevated levels of TSH. 
Nevertheless, given the high prevalence of autoimmune 
thyroid disease, the presence of thyroid autoantibodies 
does not mean that the patient might not also have TSH 
resistance.
Additional frequent clinical features
Many aspects of PHP and related disorders do not lead 
to measurable hormonal changes and are not yet rec-
ognized as being part of the spectrum of PHP- related 
disorders (Table 1).
SGA has been described in patients with a paternal 
GNAS mutation (that is, patients with PPHP or POH)106. 
Similarly, most patients with acrodysostosis and a muta-
tion in PRKAR1A or PDE4D are born SGA5,13,15. Most 
patients born SGA who have PHP or related disorders 
remain short during their adult life (with a mean final 
height in PPHP, AHO, PHP1A and acrodysostosis 
<−2 s.d.)13,15,23,86. By contrast, patients with methylation 
changes at the GNAS locus display moderately increased 
birthweight and birth length (A.L., H.J., A.H.S., G.M. 
and A.R., unpublished observations). Their final adult 
height is within the normal range107.
Although they are unspecific features, overweight 
and obesity are associated with specific PHP- related 
disorders, such as PHP1A, PHP1C and acrodysosto-
sis5,6,15,23,28,39,62,64. Patients with PHP1A and PHP1B can 
develop early- onset obesity, usually in the first 2 years 
of life28,44,49,108–111. Noticeably, obesity in adulthood is less 
severe and less common than in childhood28. Patients 
with PHP1A might also experience reduced insulin 
sensitivity112,113.
Cognitive impairment is commonly reported in 
patients with PHP or related disorders; however, its 
exact prevalence is not known, as the results of objective 
standard tests are rarely reported (40–70% of patients 
with PHP1A, 0–10% of patients with PPHP or POH, 
rare in patients with PHP1B and of variable prevalence 
in patients with acrodysostosis)1,18,23,24,26,42.
Elevated levels of calcitonin are found in a large sub-
set of patients with PHP1A and PHP1B, after exclusion 
of medullary thyroid carcinoma. Elevated levels of cal-
citonin might be considered as a marker of hormone 
resistance in a patient with a PHP or related disorder114,115
Resistance to gonadotropins seems to be less severe 
than resistance to other hormones, such as PTH and 
TSH; laboratory abnormalities indicating elevated levels 
of luteinizing hormone (LH) or follicle- stimulating hor-
mone (FSH) have been reported by some groups116–121, 
whereas others could not confirm these findings122–127. 
These findings have led to the hypothesis that 
patients with PHP1A display only partial resistance to 
gonadotropins120.
Although nonspecific symptoms such as early- onset 
obesity, short stature and/or hypothyroidism might be 
present in early infancy or childhood, the diagnosis is 
often delayed or not recognized until early puberty for 
patients with PHP1A and acrodysostosis or until ado-
lescence or adulthood for patients with PHP1B, unless 
the family history is positive. The presence of ectopic 
ossifications (which are disease- specific) might trigger 
an earlier diagnosis of POH or osteoma cutis.
Differential diagnoses
The differential diagnosis of patients with obesity, 
early- onset (even congenital) hypothyroidism, short 
stature and/or brachydactyly is very broad and includes 
many endocrine and syndromic diseases (Table 2). 
Some features, however, should prompt the clinician 
to consider diagnoses other than PHP or related dis-
orders. These features include additional bone anom-
alies, such as syndactylies, exostoses or Madelung 
deformity128, and/or facial dysmorphism or other 
features suggestive of Turner syndrome or tricho–
rhino–phalangeal syndrome72,129. The main differential 
diagnosis of ectopic bone formation is FOP. Severe vita-
min D deficiency or hypomagnesaemia might mimic 
PTH resistance130,131. A correct diagnosis can have 
extremely important implications for management, as 
it enables early screening and treatment of endocrine 
complications such as PTH and TSH resistance, pre-
vention and management of obesity and short stature, 
management of ossifications and accurate genetic and 
prenatal counselling.
Evolution of PHP classification
The first classification system distinguished PHP vari-
ants as PHP1A, PHP1B, PHP1C and PPHP1,2,27,29,69,132,133. 
The subtype assignment is based on the presence or 
absence of AHO together with characterization of 
hormone resistance and determination of Gsα pro-
tein activity using in vitro assays132,133. In addition, this 
classification excludes phenocopies of PHP, such as 
acrodysostosis and POH. Since the diseases were molec-
ularly characterized, it has become evident that clinical 
phenotypes often fail to differentiate between PHP 
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subtypes43,103,134,135. The overlap between the diseases 
(Table 1 and Supplementary Table 1) renders the diagno-
sis complex and the classification inadaptable and obso-
lete. In addition, the tools to investigate patients have 
evolved, measurement of Gsα activity in cell membranes 
is not readily available and molecular genetic diagnosis 
has become the gold standard by which PHP variants 
are distinguished17.
Recommendations
1.13.  Consider genetic diagnosis in patients who present 
with one or more major criteria suggestive of PHP 
and related disorders (A+++).
1.14.  The classification of PHP and related disorders 
should be amended to include the following (A++):
•	 A common pathophysiological framework
•	 A molecular genetic classification
Table 2 | Differential diagnoses of PHP and related disorders based on the main clinical presentation
Leading symptom Differential diagnosis Associated signs or comments
Hypocalcaemia with  
elevated PTH
Vitamin D deficiency or resistance57,130 • Improvement upon vitamin D therapy
• Rickets and alopecia also seen
Rickets268 Enlargement of the metaphyses, leg bowing and elevated ALP
Hypoparathyroidism due to a mutation in the PTH gene269 Use different assays to confirm the elevated PTH
Brachydactyly Tricho–rhino–phalangeal syndrome due to TRPS1 
mutations259
• Dysmorphism: slowly growing and sparse scalp hair, 
laterally sparse eyebrows, bulbous tip of the nose, long flat 
philtrum, thin upper vermillion border and protruding ears
• Hip dysplasia, small feet and a short hallux, exostosis and 
ivory epiphyses
Isolated brachydactyly type E due to HOXD13 
mutations270
• Syndactyly , long distal phalanges and shortening of the 
distal phalanx of the thumb
• Hypoplasia or aplasia, lateral phalangeal duplication and/
or clinodactyly
Brachydactyly mental retardation syndrome due to 
2q37 microdeletions271
Obesity , short stature, brachydactyly and psychomotor and 
cognitive alterations
Turner syndrome due to partial or complete loss of one 
X chromosome272
Short stature, low birthweight, gonadal failure and variable 
neurocognitive defects; brachydactyly and Madelung 
deformity
Brachydactyly type E with short stature due to PTHLH 
mutations75,273
Short stature of variable severity and impaired breast 
development; oligodontia, delayed tooth eruption and 
dental malposition; pseudoepiphyses and brachydactyly
Ossifications (subcutaneous) Acne vulgaris80 Superficial nodules but no ossification at pathology
Cutaneous tumours, primarily pilomatricomas, 
chondroid syringomas and basal cell carcinomas, and 
pilar cysts and nevi80; secondary or traumatic osteoma 
cutis and miliary osteoma
• No ossification at pathology
• For secondary osteoma cutis: history of trauma and burn
Inflammatory conditions such as scars, chronic venous 
stasis, morphea, scleroderma, dermatomyositis and 
myositis ossificans progressiva80
No ossification at pathology
Ossifications (progressive) FOP due to a recurrent activating missense mutation of 
ACVR1 (reF.10)
Progressive ossification of skeletal muscle, tendons, fascia 
and ligaments; upper back and neck are the first parts 
of the skeleton to be affected; trauma alters the natural 
progression of the disease; congenital malformation of the 
great toes
Tumoural calcinosis due to FGF23 or GALNT3 
mutations274
Deposition of calcium within the skin and/or muscles and 
hyperphosphataemia
Early- onset obesity Beckwith–Wiedemann syndrome104,210 Hemihypertrophy and macroglossia
Genetic, cytogenetic or syndromic anomalies 
associated with early- onset obesity , including 
Prader–Willi syndrome and monogenic obesity 
(mutations in POMC, MC4R, leptin and the leptin 
receptor)46,275
Progression of obesity through childhood; possible 
associated features, such as red hair and hypoadrenalism
Early- onset hypothyroidism Congenital hypothyroidism of any cause46,47 Small thyroid and TSH moderately elevated; no other 
associated features
TSH resistance due to mutations in the TSH receptor276 Small thyroid and TSH moderately elevated; no other 
associated features
Hypertension Autosomal dominant hypertension and brachydactyly 
type E syndrome239
Short stature
The list of differential diagnoses is not exhaustive but mentions the main diseases that overlap with pseu do hy popar ath yroi dism (PHP) and related disorders. ALP, 
alkaline phosphatase; FOP, fibrodysplasia ossificans progressive; PTH, parathyroid hormone.
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Molecular diagnosis
A positive molecular test provides important confirma-
tion of the clinical diagnosis and allows the categoriza-
tion of a patient into a specific subtype of PHP, which 
can guide management.
Annotation of each variant (including the interpre-
tation of the variant according to international guide-
lines136) and its association with the clinical findings 
within the curated Leiden Open Variation Database 
(LOVD) could improve our knowledge of the correlation 
between molecular defects and phenotype.
Molecular confirmation
GNAS locus. As previously mentioned, the main subtypes 
of PHP are caused by de novo or autosomal dominantly 
inherited inactivating genetic pathogenic variants or epi-
genetic alterations (sporadic or genetic- based) within or 
upstream of the GNAS locus. This region gives rise to 
multiple non- coding and coding transcripts, including 
those encoding Gsα (Supplementary Fig. 1a). GNAS, the 
gene that encodes Gsα, is an imprinted gene. It shows 
biallelic expression in most studied tissues, whereas 
primarily maternal expression is observed in some 
tissues (thyroid, renal proximal tubule, pituitary and 
ovary)52,137–140. This tissue- specific monoallelic expres-
sion of Gsα explains most of the clinical outcomes that 
depend on the parental origin of the GNAS mutation. 
For instance, because the paternal Gsα allele is mostly 
silenced in the renal proximal tubule, GNAS mutations 
on this allele do not impair Gsα activity. By contrast, if 
a GNAS mutation is inherited maternally or if it occurs 
de novo on the maternal allele, then Gsα levels and/or 
activity are drastically reduced, leading to PTH resist-
ance in the renal proximal tubule. The molecular and 
genetic mechanisms underlying GNAS- related disorders 
are reviewed further in multiple other articles33,141,142.
In brief, PHP1A is caused by inactivating variants on 
the maternal allele of the GNAS gene within exons 1–13 
(referring sequences NG_016194.1/NM_001077488.1 
and LRG_1051), including both point mutations and 
rare gene rearrangements16,23,27,41,45,86,88,97,112,122,143–148 
(Supplementary Fig. 1b). Mutations can be either mater-
nally inherited or de novo, with both types of mutation 
having similar incidences17. When mutations affect the 
paternal allele, they mainly cause PPHP but can also be 
responsible for osteoma cutis or POH23,41,83,86,122,145,147,149. 
Point mutations can be easily detected by sequencing 
(either Sanger sequencing or next- generation sequenc-
ing (NGS); particular attention should be given to exon 1 
in the latter method, as this exon is particularly CG- rich 
and coverage might be incomplete150), whereas genomic 
rearrangements can be analysed by quantitative meth-
ods, such as multiplex ligation- dependent probe ampli-
fication (MLPA) or comparative genomic hybridization 
arrays (aCGH)144.
By contrast, patients with PHP1B show abnormal pat-
terns of methylation in the DMRs associated with the 
GNAS complex locus45,47,86–88,101,143,151–154. A methylation 
defect can be classified as partial or complete and can 
affect one or multiple DMRs within 20q13 (reF.155). GNAS 
shows differential methylation at four distinct DMRs: one 
paternally methylated- DMR (GNAS- NESP:TSS- DMR) 
and three maternally methylated- DMRs (GNAS- 
AS1:TSS- DMR, GNAS- XL:Ex1-DMR and GNAS 
A/B:TSS- DMR, according to the current nomencla-
ture156). Loss of methylation at GNAS A/B:TSS- DMR is 
detected in all patients with PHP1B45,47,86–88,101,143,151–154.
Of the PHP1B cases, 15–20% are familial, with an 
autosomal dominant mode of inheritance (AD- PHP1B) 
through the maternal lineage17. In this familial form, the 
methylation defect is usually limited to loss of methy-
lation at GNAS A/B:TSS- DMR, secondary to a 3 kb 
microdeletion on the maternal allele of cis- acting control 
elements within STX16 (reF.157). Other maternally inher-
ited deletions and duplications have also been identified 
in some rare familial cases affecting either an isolated 
GNAS A/B:TSS- DMR66,158–160 or all four DMRs50,159,161–163 
(Supplementary Fig. 1c).
In nearly all sporadic cases of PHP1B, two or more 
DMRs, in addition to GNAS A/B:TSS- DMR, are also 
affected, for which no underlying genetic mecha-
nism has been identified154 (Supplementary Fig. 1d). 
In around 8–10%17,102 of these sporadic cases, the meth-
ylation defects are caused by paternal uniparental iso-
disomy of the chromosomal region comprising GNAS 
(UPD(20q)pat)164–168 (Supplementary Fig. 1e).
To date, very few cohorts of patients with PHP1B have 
been extensively screened for multilocus imprinting dis-
turbance (MLID). The incidence of MLID associated 
with PHP1B ranges from absent169 to 38%92, with most 
studies quoting a frequency in between these values. 
This variation can be partially explained by the small 
number of patients investigated in each study, the low 
sensitivity of molecular techniques or the total number 
of imprinted loci assessed. Consistent with most stud-
ies of MLID, patients with PHP1B- MLID do not show 
evidence of phenotype differences, and robust meth-
ylation changes are restricted to those with a sporadic 
cause89,92,104,170,171. Despite the important advances made 
with high- density methylation array screening, bio-
informatic standardization is required to ensure accurate 
comparisons between cohorts and accurate description 
of methylation disturbance in individual patients.
GNAS methylation defects can be detected through 
the use of several methods. Methylation-sensitive MLPA 
(MS-MLPA) enables interrogation of multiple regions 
in a single reaction. A kit from MRC- Holland is avail-
able (MS- MLPA ME031 GNAS) to determine the level 
of methylation at multiple GNAS sites and to screen for 
STX16 and NESP/AS deletions and deletions encom-
passing GNAS172. Alternative techniques used for the 
detection of methylation defects, but that cannot dis-
criminate epigenetic abnormalities as a result of GNAS  
deletions, include combined bisulfite restriction analy sis 
(COBRA), pyrosequencing, methylation-sensitive 
single nucleotide primer extension (MS- SNuPE) 
and EpiTYPER155,157,169.
When testing for disomy, the identification of the two 
(identical) replica copies of a single homologue of a pater-
nal 20q chromosome can be analysed either by micro-
satellite or short tandem repeat (STR) typing (analysis 
of the trio, that is, parents and the index case, might be 
essential for definitive conclusions) or by performing a 
single- nucleotide polymorphism (SNP) array164,165,167.
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On the basis of the different molecular alterations, 
molecular testing must be able to robustly and accu-
rately detect point mutations, genetic or genomic 
rearrangements and methylation defects.
PRKAR1A and PDE4D. Only heterozygous point muta-
tions in PRKAR1A (referring sequence NC_000017.11/
NM_002734.4) or PDE4D (referring sequence 
NG_027957.1/NM_001165899) have been associated 
with acrodysostosis5,6,13–15,20,62–64.
Other genetic or genomic alterations have been 
identified in these genes, but they are not associated 
with PHP and related disorders. For example, hetero-
zygous genomic rearrangements (deletions and duplica- 
tions) at 5q12.1 encompassing PDE4D are associated 
with a novel intellectual disability syndrome (OMIM 
#615668) without acrodysostosis and with a specific 
phenotype that diverges from that of patients with point 
mutations in PDE4D14. Furthermore, mutations and 
deletions in 17q24.2-q24.3 encompassing PRKAR1A 
have been associated with Carney complex173, which 
results from activation of protein kinase A signalling174.
Recommendations
2.1.  Molecular diagnosis of individuals with a suspected 
diagnosis of PHP must include DNA sequence, 
methylation and copy number variant (CNV) 
analyses at the GNAS locus (Fig. 2) (A++).
2.2.  When the clinical pattern is highly suggestive of 
alteration of a specific gene, Sanger sequencing of 
that gene is proposed (A++).
2.3.  When the clinical presentation is not suggestive of 
a specific gene, a targeted gene panel encompassing 
genes that encode proteins involved in the PTH–
parathyroid hormone- related protein (PTHrP) sig-
nalling pathway might be performed. If gene panel 
sequencing is used, it should fulfil the recommended 
guidelines175 for design and reporting (A++).
2.4.  If a sequence variant is identified in any gene associ-
ated with PHP and related disorders, its pathogenic-
ity should be assessed according to the established 
standards and guidelines136 (A+++).
2.5.  The parental origin of the variant could have impor-
tant clinical implications; thus, parental testing 
is indicated when a genetic alteration is detected 
(A++).
2.6.  If the variant is de novo, the allelic origin might have 
to be determined (B+++).
2.7.  In certain cases, such as UPD(20q)pat or gross dele-
tions, additional genetic studies might be advisable 
(A++).
2.8.  Technical limitations must be taken into consider-
ation when reporting negative results and included 
in the genetic report. For instance, mosaicism can 
be considered if a negative result is observed in a 
patient with high clinical suspicion through analysis 
of tissues other than blood (for example, saliva or a 
buccal swab) or the use of alternative techniques, 
such as deep sequencing (A++).
2.9.  For each de novo pathogenic variant, or variants of 
unknown significance, parental germline mosaicism 
should be considered (A++).
2.10.  After exclusion of alterations in genes associated 
with PHP and related disorders, the patient should 
be referred to an expert centre (A++).
Genetic counselling
Despite the clinical and molecular overlap between 
PHP and related disorders (Table 1 and Supplementary 
Table 1), once the molecular defect is identified, genetic 
counselling is available for patients and families in most 
expert centres.
No correlation exists between the severity of 
the parental phenotype and that of the affected off-
spring, as interfamilial and intrafamilial variability 
has been observed for the same mutation, and the 
imprinting effect at the GNAS gene also affects clinical 
outcomes16,64.
When dealing with GNAS gene defects, the parental 
origin of the mutation and clinical heterogeneity make 
genetic counselling a challenging task, mainly owing to 
four factors. First, paternal inheritance (or a mutation 
in the paternal allele) can lead to either a mild expres-
sion of PPHP or a severe expression of POH. Why 
paternal inheritance of a GNAS mutation should result 
in PPHP in some families and POH in others remains 
unclear10,74,84. Second, when the mutation involves the 
maternal allele, it will lead to PHP1A or PHP1C. Third, 
patients have a 50% chance of transmitting the molecu-
lar defect, and depending on their sex, the descendant 
will develop PPHP or POH (when the patient is male) or 
PHP1A or PHP1C (when the patient is female). Fourth, 
there is no clear correlation between the type or location 
of GNAS mutations and the disease onset, severity of 
endocrine resistance, neurocognitive phenotype or the 
number of AHO features.
When methylation alterations at the GNAS locus 
are present, the recurrence risk depends on the under-
l ying genetic defect, if present, and the parental origin. 
Paternally inherited STX16 or NESP/AS deletions are not 
associated with methylation defects, so that the descend-
ants of a male carrying any of these deletions have a 50% 
chance of inheriting the genetic defect; however, if they 
inherit the genetic defect, their GNAS methylation status 
will be normal, and they will not develop PHP1B157. If a 
female carries the STX16 or NESP/AS deletion, each of 
her descendants has a 50% risk of inheriting the genetic 
defect, and if the descendant inherits the defect, he or she 
will present with a methylation defect affecting only GNAS 
A/B:TSS- DMR or the complete GNAS locus (depending 
on the inherited deletion)18. In both cases, the descendant 
will develop PHP1B45,47,86–88,101,143,151–154. Although translo-
cations of chromosome 20 resulting in UPD(20)pat are 
very rare, parental karyotyping is recommended to estab-
lish the risk of recurrence. If no genetic alteration can be 
identified that is associated with the methylation defect, 
the recurrence and transmission risks are expected to be 
similar to that of the general population.
Pathogenic variants at PRKAR1A and PDE4D mostly 
occur de novo5,6,13–15,20,62–64. According to the pattern of 
autosomal dominant inheritance, patients have a 50% 
of chance of passing on the molecular defect and the 
disease to their descendants, independently of the sex 
of either the progenitor or the descendant.
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Fig. 2 | Molecular algorithm for the confirmation of diagnosis of PHP and related disorders. If patients present with Albright 
hereditary osteodystrophy (AHO), genetic alterations at GNAS should be studied, including point mutations (sequencing) and 
genomic rearrangements (such as multiplex ligation- dependent probe amplification (MLPA) and comparative genomic 
hybridization arrays (aCGH)). Once the variant is found, its pathogenicity should be confirmed according to guidelines136, and, 
when possible, the parental origin should be determined. In the absence of AHO, epigenetic alterations should be analysed first. 
According to the results obtained for the methylation status, further tests are needed to reach the final diagnosis: if the 
methylation defect is restricted to transcription start site (TSS)–differentially methylated region (DMR) at exon A/B of GNAS 
(GNAS A/B:TSS- DMR), STX16 deletions should be screened for, and, if present, the diagnosis of autosomal dominant- 
pseu do hy popar ath yroi dism type 1B (AD- PHP1B) is confirmed; if the methylation is modified at the four DMRs, paternal 
uniparental disomy of chromosome 20 (UPD(20q)pat) should be screened for ; in absence of UPD(20q)pat, deletions at NESP 
should be screened for ; if no genetic cause is identified as the cause of the methylation defect, the sporadic form of the disease 
(sporPHP1B) is suspected. After exclusion of the GNAS locus as the cause of the phenotype, and in patients with AHO, pseu do-
hy popar ath yroi dism (PHP)-related genes (that is, at least PDE4D and PRKAR1A) should be sequenced. Squares in light red indicate 
the technology ; blue, the final molecular confirmation; red, no molecular alteration; and grey , future or research steps are 
suggested. ICRs, imprinting control regions; MLID, multilocus imprinting disturbance; NGS, next-generation sequencing; PHP1A , 
pseu do hy popar ath yroi dism type 1A; PHP1B, pseudohypoparathyroidism type 1B; POH, progressive osseous heteroplasia; PPHP, 
pseudopseu do hy popar ath yroi dism; RT-PCR , reverse-transcription PCR; SNP, single- nucleotide polymorphism; STRs, short tandem 
repeats (microsatellites); UPD, uniparental disomy ; VUS, variant of unknown significance; WES, whole-exome sequencing; WGS, 
whole-genome sequencing.
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The identification of a pathogenic variant in an 
index case enables a correct diagnosis and the possi-
bility of predictive genetic testing in relatives, which 
can be excluded from further follow- up if the result is 
negative176. In parents of an index case, it is essential to 
exclude mosaicism116,177,178 or to indicate this possibility 
at the counselling session.
Recommendations
2.11.  Genetic counselling should be adapted to the 
different molecular findings for the GNAS locus 
(B++) and the PRKAR1A and PDE4D genes (A++) 
according to Table 3.
Prenatal testing
There are very few cases with antenatal diagnosis of 
PHP or PPHP, as their clinical manifestations (including 
growth retardation, subcutaneous ossifications and TSH 
resistance) are usually not specific within this period. 
The bone dysplasia observed in patients with acrodysos-
tosis might display a prenatal onset, mostly when caused 
by PRKAR1A mutations6.
Recommendations
2.12.  Even if all the molecular defects associated with PHP 
and related disorders were known and technically 
available for testing in preimplantation or prena-
tal diagnosis, ethical and legal concerns regarding 
the pertinence of performing these tests should be 
taken into consideration, with appropriate genetic 
counselling (A++).
2.13.  If prenatal testing is considered, methylation 
analysis is not recommended (A++).
Management
To date, no prospective clinical trials have been con-
ducted in patients with PHP and related disorders that 
focus on the management and outcomes of treatment in 
these disorders. Large cohorts of molecularly diagnosed 
patients are needed for recruitment into clinical stud-
ies, which should also include long- term follow- up. As 
a result of the rarity of the disease, cohorts and research 
forces are scattered; there is a need to coordinate and 
implement multicentre international clinical trials.
A multidisciplinary follow- up and early, specific 
interventions are necessary for efficient therapeutic 
management of these patients. Table 4, which is based 
on the literature analysis and authors’ expertise, summa-
rizes the main interventions that should take place during 
the follow- up of patients with PHP and related disorders 
and gives a suggested frequency for the interventions.
Recommendation
3.1.  The diagnosis and management of patients with 
PHP and related disorders should be performed by 
a multidisciplinary team of specialists (A++).
Management of PTH resistance
Even though PTH resistance is the hallmark of PHP and 
is referenced in the name of the disorder, very few stud-
ies have focused on the natural history of its appearance, 
and almost none on its management.
Long- term treatment of hypocalcaemia associated 
with PTH resistance is similar but usually more aggres-
sive than that of primary hypoparathyroidism, with 
the use of active vitamin D metabolites (calcitriol) or 
analogues (alfacalcidol) and oral calcium supplements 
as and when required179. The current approach is to 
reduce the serum level of PTH to the upper portion of 
the reference range to avoid suppression of PTH, which 
can be associated with hypercalciuria and renal calcifi-
cation. Serum levels of PTH that are at the upper limits 
of the reference range are sufficient to enhance calcium 
reabsorption in the distal renal tubule, thus helping to 
prevent hypercalciuria34. However, PTH levels should 
not be too high, as long- standing PTH excess might 
have adverse effects on skeletal mineralization or on 
the growth plate71,180–182. Accordingly, treatment with 
oral calcium and active vitamin D supplementation can 
be used to target a higher serum level of calcium than 
in patients with PTH- deficient hypocalcaemia, where 
treatment targets the low–normal or slightly reduced 
range of calcium. As a result of the preserved sensitivity 
of the distal convoluted tubules, patients with PHP and 
related disorders very rarely develop hypercalciuria34. 
However, several experts involved in this Consensus 
Statement have encountered episodes of nephrolithiasis 
in patients with PHP1A and PHP1B, particularly after 
completion of pubertal growth, when the doses of oral 
calcium and active vitamin D analogues can be reduced 
(G.M., P.K, A.R. and A.L., unpublished observations).
Chronic hypocalcaemia and associated hyperphos-
phataemia can result in intracranial deposition of cal-
cium, a feature usually referred to as Fahr syndrome65. 
These calcifications occur predominantly in the basal 
ganglia but might extend widely to the thalami and the 
cortex. This form of ectopic calcification is due to ele-
vated levels of the calcium–phosphorus product and 
hence has not been described in patients with PPHP 
or POH or those with a mutation in the PRKAR1A or 
PDE4D genes5,6,8,62,183,184.
Other ectopic depositions of calcium and phospho-
rus occur in the eyes, which lead to cataracts (peripheral 
lenticular opacities). Corneal opacities, macular degen-
eration, nystagmus, anisocoria, papilloedema, tortuos-
ity of retinal vessels and microphthalmia have also been 
reported8,185–188.
Long- term and excessive secondary hyperparathy-
roidism can result in osteitis fibrosa cystica and slipped 
capital femoral epiphysis, which might require a com-
bination of medical and surgical management189,190. 
Patients with GNAS mutations involving the paternal 
allele or PDE4D mutations usually do not develop PTH 
resistance over time15,20,23,60,62,63.
Additional complications of PTH resistance include 
dental manifestations, such as failure of tooth eruption, 
short blunted roots, dental pulp alterations, hypodon-
tia and enamel hypoplasia. Finally, increased uric acid 
excretion has been reported in two families with PHP1B, 
which suggests a possible role for PTH resistance in the 
renal handling of this analyte191,192. Increased excretion 
of uric acid and phosphorus might increase the risk of 
developing kidney stones if urinary levels of calcium 
are increased. These last complications, when present, 
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should be managed according to good clinical practice. 
No specific recommendations can be formulated at the 
moment given the rarity of their presentation.
Recommendations
3.2.    At diagnosis or before initiation of treatment, 
we recommend the monitoring of serum levels 
of PTH, calcium, phosphorus and calcifediol. 
Measurement of PTH, calcium and phosphorus 
should be performed regularly (every 6 months 
in children and at least yearly in adults) with the 
exception of patients carrying either a GNAS muta-
tion on the paternal allele or a PDE4D mutation in 
whom, apart from at diagnosis, routine assessment 
is not necessary. Monitoring of serum levels of cal-
cium should be more frequent in symptomatic 
individuals, during acute phases of growth, during 
acute illness and during pregnancy and breastfeed-
ing, when dose requirements for active vitamin D 
metabolites or analogues might change. Calcifediol 
levels should be normalized and maintained in the 
normal range in all patients (A+++).
3.3.    Severe symptomatic hypocalcaemia requires 
immediate correction, which might include intra-
venous administration of calcium salts according 
to general guidelines for the management of acute 
hypocalcaemia in hypoparathyroidism179. These 
patients should also be concomitantly treated with 
active vitamin D metabolites or analogues (A+++).
3.4.    In patients with substantial and progressive increases 
in levels of PTH and hyperphosphataemia, treatment 
with active vitamin D metabolites or analogues 
could be considered, independently of the presence 
of hypocalcaemia. Calcium supplements should be 
considered, depending on the dietary calcium intake. 
Serum levels of phosphorus should be monitored 
during treatment with vitamin D metabolites or 
analogues and calcium supplements (A++).
3.4.b.  Treatment with active vitamin D metabolites or 
analogues could also be considered when lev-
els of PTH are more than twice the upper level 
of normal, independently of the presence of 
hypocalcaemia (B+).
3.5.    The objectives of conventional management of 
PTH resistance include maintenance of serum lev-
els of calcium and phosphorus within the normal 
range while avoiding hypercalciuria (age and size 
corrected) and lowering PTH levels as permitted 
by serum and urinary levels of calcium. We recom-
mend the use of the active vitamin D metabolite 
Table 3 | Guidance for genetic counselling in PHP and related disorders according to each molecular defect
Locus Molecular 
diagnosis
Molecular defect Affected 
allele
Cases  
(n or %)
Theoretical 
recurrence risk 
(when inherited)
Clinical predictive 
outcome
Further tests
GNASa Genetic defect Heterozygous loss- 
of-function mutation
Mat 35.9% 50% Affected pt PHP1A Maternal testing 
for carrier status
Pat 5.9% 50% Affected pt PPHP and/
or POH
Paternal testing 
for carrier status
Partial or total locus 
deletion or inversion
Mat 1.8% 50% Affected pt PHP1A Maternal testing 
for carrier status
Pat 0.2% 50% Affected pt PPHP and/
or POH
Paternal testing 
for carrier status
Sporadic 
methylation defect
Broad LOI (all GNAS 
DMRs)
Mat 38% ND Affected pt sporPHP1B Research
Isolated LOM GNAS 
A/B:TSS- DMR
Pat 2% ND Affected pt sporPHP1B Research
Uniparental disomy 
(UPD(20q)pat)
– 2.7% Low; high when 
a translocation is 
present
Affected pt sporPHP1B Chromosome 
analysis of 
proband and 
father
Inherited 
methylation defect
Isolated LOM GNAS 
A/B:TSS- DMR + STX16 
ICR deletion
Mat 13.5% 50% Affected pt AD- PHP1B Maternal testing 
for carrier status
STX16 ICR deletion Pat ND 50% Unaffected carrier Not required
Broad LOI + NESP/AS 
ICR deletion
Mat ND 50% Affected pt AD- PHP1B Maternal testing 
for carrier status
NESP/AS ICR deletion Pat ND 50% Unaffected carrier Not required
PRKAR1Ab Genetic defect Heterozygous mutation Not relevant 79 50% Affected pt Parental testing 
for carrier status
PDE4Db Genetic defect Heterozygous mutation Not relevant 43 50% Affected pt Parental testing 
for carrier status
AD- PHP1B, autosomal dominant pseu do hy popar ath yroi dism type 1B; DMR , differentially methylated region; ICR , imprinting control region; LOI, loss of imprinting; 
LOM, loss of methylation; Mat, maternal; ND, not determined; Pat, paternal; PHP, pseudohypothyroidism; PHP1A , pseu do hy popar ath yroi dism type 1A ; POH, progressive 
osseous heteroplasia; PPHP, pseudopseu do hy popar ath yroi dism; pt, patient; sporPHP1B, sporadic pseu do hy popar ath yroi dism type 1B. aPercentages obtained from Elli 
et al.17 bNumbers extracted from the corresponding Leiden Open Variation Database (LOVD) web referred to total carriers with public variants (it varies with time).
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calcitriol or the active vitamin D analogue (alfa-
calcidol) with or without calcium supplementation 
as the mainstay of treatment of chronic hypo-
calcaemia. Patients should not be treated with 
PTH or PTH analogues. During treatment, levels 
of PTH, calcium and phosphorus should be mon-
itored every 6 months in asymptomatic patients 
and more frequently when clinically indicated. 
Patients and/or their family should be instructed 
about symptoms and signs of hypocalcaemia and 
hypercalcaemia (A++).
3.6.    We recommend appropriate renal imaging to 
evaluate nephrocalcinosis at transition (B+).
3.7.    We recommend age- appropriate179 renal imaging 
to monitor for the development or worsening of 
nephrocalcinosis in patients with persistent hyper-
calciuria on repeated measurements and as clini-
cally indicated (B++).
3.8.    For the evaluation of long- term consequences of 
hypocalcaemia and hyperphosphataemia, a brain 
CT scan is indicated only when neurological man-
ifestations are present. Ophthalmological exami-
nation is recommended to diagnose or exclude 
cataracts (A++).
3.9.    Phosphate binders (other than calcium) are rarely, 
if ever, indicated in the management of severe and 
long- term persistent hyperphosphataemia (B++).
3.10.   We recommend regular dental reviews every 
6–12 months during childhood and as clinically 
indicated in adults (A++).
Management of TSH resistance
In patients with PHP1A, the average level of TSH is 
14.1 ± 10.3 mUI/l, with a range of 1.4 mUI/l to 46.0 mUI/l 
( r e F s 2 4 , 3 0 , 3 8 , 6 7 , 9 8 , 1 0 0 , 1 1 7 , 1 1 9 , 1 2 2 , 1 2 3 , 1 2 9 , 1 4 4 – 1 4 6 , 1 4 9 , 1 9 3 – 2 0 5 ) . 
A prompt diagnosis of hypothyroidism after birth and 
initiation of treatment does not seem to prevent the 
development of motor or cognitive delay24.
In patients with PHP1B, the degree of TSH resistance 
can vary with time52,53,102,206. The average level of TSH 
is 5.3 ± 4.7 mUI/l (4.8 ± 3.4 mUI/l and 5.4 ± 5.2 mUI/l 
in autosomal dominant PHP1B and sporadic PHP1B, 
respectively), ranging from 0.8 mUI/l to 50.0 mUI/l 
(reFs36,44,46–49,51,53,54,87,89,91,102,105,131,143,153,164,166,169,178,200,206–210).
The literature does not contain specific data on how 
to treat TSH resistance in patients with PHP and related 
disorders. Indications for treatment, drug formulations, 
doses and target serum concentrations of TSH and T4 
Table 4 | Summary of the main interventions during the follow- up of patients with PHP and related disorders
Action points Infancy (newborn 
to 2 years)
Early childhood 
(2–6 years)
Late childhood to 
adolescence
Adulthood
Anticipatory guidance
Family support ✓ ✓ ✓ NA
Genetic counselling At diagnosis At diagnosis At diagnosis At diagnosis
Medical evaluation
Linear growth ✓ ✓ ✓ NA
Weight gain and BMI ✓ ✓ ✓ ✓
Descended testis ✓ ✓ If not checked before If not checked 
before
Blood pressure NA ✓a ✓ ✓
Development and/or 
cognition
✓ ✓ S S
Psychosocial evaluation NA ✓ S S
Ectopic ossifications ✓ ✓ ✓ S
Orthodontic and/or dental NA ✓ ✓ S
Bone age radiography NA ✓ (in case of growth 
deceleration)
✓ (in case of growth 
deceleration)
NA
Calcium–phosphorus 
metabolism
✓ ✓ ✓ ✓
Age- appropriate renal 
imaging
✓b ✓b ✓ ✓b
Thyroid ✓ ✓ ✓ ✓
Puberty NA NA ✓ (biochemistry in 
case of retardation)
NA
GH secretion NA ✓ ✓ S
Glucose and lipid metabolism NA ✓ ✓ ✓
Fertility NA NA S S
GH, growth hormone; NA , not applicable; PHP, pseu do hy popar ath yroi dism; S, subjective (by history and physical examination);  
✓, to be performed at diagnosis and annually thereafter. aAt least once per year, with an appropriate sized cuff. bAnnually in case  
of increased excretion of urinary calcium or nephrocalcinosis.
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should be the same as those used in any other form of 
hypothyroidism or subclinical hypothyroidism.
In general, patients should be screened for auto - 
i mmune thyroid disease. Nevertheless, because autoimmune 
thyroid disease is highly prevalent, the presence of auto-
immunity will not rule out concomitant TSH resistance 
in a given patient (see recommendation 3.11).
Recommendations
3.11.  Evaluation of thyroid function (including autoanti-
bodies in adolescents and adults) for early detection 
of TSH resistance and early intervention is recom-
mended in all patients with PHP and related dis-
orders at diagnosis. Thereafter, TSH monitoring is 
recommended every 6 months in patients <5 years 
of age and yearly in older children and adults (A++).
3.12.  The indication or indications to treat hypothyroid-
ism, the dosage of levothyroxine and the therapeu-
tic goals should be the same as for any patient with 
hypothyroidism or subclinical hypothyroidism211–213 
(A++).
Management of growth and GH deficiency
With the exception of PHP1B, a large proportion 
(around 80% of patients with PHP1A, 50–70% of 
patients with PPHP and almost all patients with 
acrodysostosis) of patients with PHP and related 
disorders have adult short s ta tu re 5 ,13–1 5 , 23 , 2 4 , 28 , 3 9 , 
45 , 53,54,62–64,86,89,97,104,105,107,113,122,143,145,146,153,205,206,214–216. Overall, 
the final height deficit in patients with PHP1A and PPHP 
is severe, approximately −2.5 s.d., with mean heights of 
149 cm in women and 155 cm in men28,122,217. In patients 
with PHP1B, despite a great variability in adult height, 
mean stature is not significantly different from that of 
the general population107. Patients with acrodysostosis 
have adult heights that are even shorter than those of 
patients with PHP1A, with a mean height of −3.5 s.d. 
(−8.8 to −0.5)5,14,15,62–64. The height deficit in patients with 
PHP develops over time. Small cohorts of patients with 
PHP1A have shown declining growth velocity a few years 
after birth, a lack of a pubertal growth spurt and prema-
ture cessation of statural growth86,97,107,217. This finding is 
also supported by observations from the authors’ day- 
to-day practice (L.d.S., H.J., A.L., P.K., G.M., G.A.M.-M., 
O.M., A.R. and Su.T., unpublished observations).
Bone age is advanced by more than 2.0 s.d. 
beyond chronological age in 70–80% of patients with 
PHP1A97,215,217,218. Advanced growth plate maturation is 
consistently described in patients with acrodysostosis5,15,63. 
The severity of the dysostosis reduces the reliability of 
using bone age determinations to predict adult height219. 
We know from our practice that phalanx epiphyses might 
close as early as 3 years of age in these children (A.L., 
G.A.M.-M., A.R. and Su.T., unpublished observations).
Most patients with PHP1A (50–80%) develop GHRH 
resistance and consequently GH deficiency45,86,97,143,146,20
6,215,218. Recombinant human growth hormone (rhGH) 
treatment increased growth velocity in one study con-
ducted in eight prepubertal children with PHP1A and 
GH deficiency. It is of interest that in this study, one 
female patient whose oestrogen production was blocked 
by GnRH analogues did have evidence of a long- term 
growth advantage compared with her sister who did 
not receive the analogues217. Data from a clinical trial 
(NCT00209235)220 on final height and on the association 
of puberty blockers are pending.
Finally, in the context of prenatal growth restric-
tion, even if the GH secretion is deficient, the authors’ 
experience suggests using doses of rhGH higher than 
those usually given in children with idiopathic GH defi-
ciency, for instance, the doses used in patients with SGA 
(L.d.S., A.L., G.M. and A.R., unpublished observations). 
Overall, additional published data are required before a 
recommendation on the use of GH therapy, or any other 
growth modifying treatment, in this group of patients 
can be made.
Recommendations
3.13.  We recommend careful monitoring of height in 
children at every control examination (at least 
every 6 months) until final height is reached 
(A+++).
3.14.  We recommend monitoring of skeletal maturation 
using plain radiography in all children (with t h e 
e x c e p tion o f t h o se w i t h P H P 1B) a n d e v a lu a t ion 
f or GH deficiency in all children in the context 
of statural growth deceleration. As most patients 
develop GH deficiency due to GHRH resistance, 
clinical and/or biochemical evaluation of the GH–
insulin- like growth factor 1 (IGF1) axis should be 
performed in all patients, typically around the age 
of 3–6 years and repeated as necessary (B++).
3.15.  Patients with GH deficiency should be treated with 
rhGH. Data are needed on the outcomes of GH treat-
ment in children who are not GH deficient before 
recommending this treatment in these patients as 
well (A++).
3.16.  Adults with GH deficiency might be considered 
for treatment with rhGH; however, specific proof 
of benefit in this population is lacking, and treat-
ment should be given according to country- specific 
regulations (B++).
3.17.  Patients with PHP who are born SGA who do not 
exhibit appropriate catch- up growth might qualify 
for treatment with rhGH; however, caution should 
be exercised in patients with ectopic ossifications, as 
no data are available on the possible effect of rhGH 
treatment on the evolution of ossifications (B++).
Alterations in gonadal function
Gonadal function and puberty. The pubertal growth spurt 
might be blunted or absent in both girls and boys with 
PHP1A. Although the basis for this defect is unknown, it 
could relate to insufficient sex steroid production or pre-
mature epiphyseal closure120. Systematic data are scarcer 
for PHP1B and PPHP than for PHP1A, but these patients 
are thought to have normal gonadal function206. Similarly 
to PHP1A, variable resistance to gonadotropins has been 
described in patients with acrodysostosis and mutations 
in the PRKAR1A gene15, as well as in anecdotal reports of 
single patients with mutations in PDE4D14. Furthermore, 
despite basal gonadotropin and sex steroid levels that 
are within normal limits, menstrual irregularities seem 
to be common among female patients with PHP1A120. 
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According to the experts’ experience, cryptorchidism is 
highly prevalent in patients with PHP1A, leading to the 
hypothesis of a possible role of hormone resistance in the 
pathogenesis of PHP1A (A.L., P.K., Su.T., A.R. and G.M., 
unpublished observations).
Fertility and pregnancy. Unassisted and unevent-
ful pregnancies have been reported in female 
patients with PHP1A120,221 and autosomal dominant 
PHP1B44,72,153,160,216; these pregnancies are more often seen 
in women with PPHP, who give birth to offspring with 
PHP1A24,36,45,117,122,221–223. In a few cases, either infertility193 
or the need for the use of an assisted reproductive tech-
nique to obtain pregnancy47,224,225 have been reported. No 
data are available on lactation, but there are no specific 
reports that these patients are unable to lactate.
Menopause. No data are available on menopause and its 
timing in women with PHP and related disorders.
Osteoporosis. The prevalence of osteoporosis in patients 
with PHP and related disorders is unknown. In these 
patients, bone loss might occur as a result of untreated 
hypogonadism, long- term excess levels of PTH, GH 
deficiency and/or the onset of physiological meno-
pause. The physiological action of PTH on bone is 
mainly to promote bone resorption, but the extent to 
which PTH signalling in bone is defective in patients 
with PHP and related disorders is not completely clear. 
The bone remodelling response to PTH, which is inde-
pendent of vitamin D action, seems to be intact in these 
patients180, which suggests a possible increased risk of 
osteoporosis in patients with sustained increased lev-
els of PTH despite treatment with calcium and vitamin 
D. Nevertheless, bone density seems to be normal to 
increased in patients with PHP1A, in particular in those 
who do not have excessive circulating levels of PTH218.
Recommendations
3.18.  Tanner staging of sexual maturation should be 
performed at regular intervals to monitor puber-
tal progression in all patients with PHP or related 
disorders (A+++).
3.19.  Testicular descent and location should be 
assessed in males with PHP or related disorders. 
Cryptorchidism, when present, should be cor-
rected and managed according to the standard 
recommendations (A++).
3.20.  We do not recommend routine biochemical 
assessment of the gonadal status unless clinically 
indicated. Hypogonadism, when present, should 
be treated with sex hormones following the same 
standard criteria, doses and follow- up as any other 
form of hypogonadism (B++).
3.21.  After puberty, menstrual history should be 
collected at each follow- up visit, and biochemical 
evaluation should be requested in the presence of 
oligomenorrhoea or amenorrhoea in women and the 
presence of hypogonadal symptoms in men (B+++).
3.22.  In case of infertility, assisted reproductive treat-
ment can be considered according to national 
guidelines (A+).
3.23.  In patients with PHP and related disorders, natu-
ral and induced pregnancies should be monitored 
from an obstetrical point of view in the same way 
as any other pregnancy. However, dosages of active 
forms of vitamin D and levothyroxine might have 
to be adjusted. The possibility of vaginal delivery 
might be limited as a result of reduced pelvic size 
and decreased range of motion of the hips due to 
local ossifications (A+).
3.24.  Management of hypocalcaemia and hypothyroidism 
should follow the current guidelines available for 
the management of hypoparathyroidism and hypo-
thyroidism during pregnancy. The newborn should 
be evaluated for levels of TSH, calcium and phos-
phorus. Lactation is not contraindicated, but close 
follow- up and clinical monitoring (particularly 
of weight) of the baby are advised (B++).
3.25.  Patients with PHP and related disorders have sev-
eral potential risk factors for osteoporosis (hypo-
gonadism, chronic elevation of PTH and GH 
deficiency). However, owing to the lack of evidence 
of increased fracture risk, there is no indication to 
perform routine dual- energy X- ray absorptiom-
etry (DXA) measurements in patients with PHP 
and related disorders. If osteoporosis is diagnosed, 
management should take into account, whenever 
possible, treatment of the underlying secondary 
cause for bone loss (hypogonadism, postmenopau-
sal status or related to sustained elevation of PTH 
levels and GH deficiency) (B++).
Management of other hormone resistances
Resistance to additional hormones that mediate their 
actions through Gsα- coupled receptors, as well as pro-
lactin deficiency, has also been previously reported; 
however, the clinical relevance of these abnormalities 
remains to be established132. Early studies described the 
presence of resistance to calcitonin114, and this finding was 
 subsequently confirmed in case reports and in a small 
case series of patients with PHP1A115. Unpublished but 
 consistent observations from the authors indicate that, 
among the other hormone resistances, hypercalcitoni-
naemia is present in a substantial subset of patients with 
PHP1A and PHP1B (L.G., A.L., H.J., G.M., A.R., L.R. and 
A.H.S., unpublished observations). No published evidence 
indicates that hypercalcitoninaemia leads to clinically 
significant C cell hyperplasia or medullary thyroid carci-
noma in PHP and related disorders. Adrenal resistance to 
adrenocorticotropic hormone (ACTH) and other hor-
mone resistances are not documented to occur in patients 
with PHP1A, apart from a few old anecdotal reports.
Recommendation
3.26.  We do not recommend routine calcitonin measure-
ment or screening for additional hormone resistances 
in patients with PHP and related disorders (A+).
Obesity and other metabolic issues
Children with PHP1A and obesity show both decreased 
resting energy expenditure compared with controls with 
obesity and hyperphagic symptoms similar to those seen 
in BMI- matched controls with obesity39,111,112. In older 
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(late infancy, adolescence and young adulthood) patients, 
this hyperphagic trait seems to abate111, and energy 
expenditure seems to improve to low–normal113. As a 
consequence, obesity is less pronounced in adulthood 
than in childhood28.
With the exceptions of the case reports of a patient 
with PHP1C successfully treated with a cannabinoid 
receptor type 1 (CB1) antagonist99 and of a patient with 
PHP1A treated with a gastric bypass226, there are no 
specific reports concerning specialized management of 
obesity in these patients.
Early- onset obesity is observed not only in patients 
with PHP1A but also in patients with PHP1B44,46,86,158. The 
increased weight gain might start within the first months 
of life in some patients, similar to what is observed in 
patients with monogenic defects of the leptin–melano-
cortin pathway227,228. This finding highlights the need for 
close monitoring of weight in all patients with PHP and 
related disorders, not only in those with PHP1A.
Findings from animal models suggest that the under-
lying mechanism contributing to obesity is related to the 
effect of Gsα imprinting in the CNS. In the hypothalamus, 
Gsα signals through melanocortin229 and thereby affects 
energy expenditure. This finding suggests that drugs mod-
ifying the melanocortin pathway might be effective for 
weight control in patients with PHP and related disorders.
Sleep apnoea is a well- known complication of obe-
sity. Sleep disturbances with daytime somnolence have 
been reported in a series of patients with PHP1A230 and 
were more frequent (4.4-fold higher relative risk) than 
in participants without PHP1A who had similar levels of 
obesity230,231. Irrespective of the underlying mechanism, 
untreated sleep apnoea is associated with poor memory 
and concentration, increased risk of heart disease and 
impaired glucose metabolism232. Effective treatment of 
sleep apnoea might mitigate these risks and even improve 
school performance233. In addition to sleep apnoea, other 
pulmonary disorders (such as an increased prevalence 
of asthma) have also been associated with PHP1A 
(50–75%), PPHP and PHP1B39,46,230,234.
Metabolic consequences of PHP and related disorders 
have not been characterized. Nevertheless, in addition to 
obesity, impairment of glucose metabolism and hyper-
tension are present in a large subset of patients112,113. For 
instance, patients with PHP1A have decreased insulin 
sensitivity that appears early during childhood, which 
seems to be only partially related to the degree of obesity. 
These data have been published in single case reports109, 
as well as in two small series of children and adolescents 
(aged 2–18 years)112,113, but are also confirmed in daily 
clinical practice (A.L., G.A.M.-M., A.H.S. and A.R., 
unpublished observations).
In a series of ten children with PHP1A, levels of 
HbA1c and fasting insulin were normal in all partici-
pants but one97. By contrast, in ten adults with PHP1A, 
four already had a diagnosis of type 2 diabetes melli-
tus, the fasting plasma levels of glucose and HbA1c were 
higher than the controls with obesity, and they showed 
decreased insulin sensitivity113. These findings indicate 
that factors other than obesity might contribute to lower 
insulin sensitivity in these patients and are consistent 
with observations in a mouse model of PHP1A in which 
glucose intolerance and insulin resistance developed 
before the onset of obesity235.
As for the lipid profile in PHP and related disorders, 
in a small series of patients with PHP1A, cholesterol, 
triglycerides and/or LDL levels were either elevated or 
at the upper end of the normal range97. No data are avail-
able regarding lipid profiles in the other PHP subtypes 
and related disorders.
Finally, blood pressure and its regulation have been 
very poorly investigated in PHP and related disorders, 
and the scarce available data date back to the 1980s236. 
Nevertheless, hypertension is frequently observed in 
young adults with PHP and related disorders. In 1988, 
elevated blood pressure was reported in 53% of adult 
patients with PHP and related disorders, with a similar 
prevalence in clinically defined patients with PHP1A 
and PHP1B237. More recently, the case of a young patient 
with PHP1B who had juvenile renin- dependent hyper-
tension has been reported238. A direct link between the 
cAMP signal transduction pathway and hypertension 
has been demonstrated by the finding of PDE3A muta-
tions in families with autosomal dominant hyperten-
sion and brachydactyly type E syndrome21,239, and the 
mechanism underlying hypertension in these patients 
is thought to be related to increased peripheral vascular 
resistance due to vasoconstriction.
Recommendations
3.27.  We recommend regular monitoring of BMI and 
eating behaviour (Table  4). Educational pro-
grammes, as well as psychological support, should 
be provided to patients and families when obesity 
and/or eating disorders are present and even in the 
presence of a normal BMI as a preventive strategy, 
as these patients are at high risk. Dietary counsel-
ling should take into account that these patients 
have decreased resting energy expenditure (A++).
3.28.  We recommend that all patients with PHP and 
related disorders should be evaluated for symptoms 
such as restless sleep, snoring, inattentiveness and 
daytime somnolence, and, if symptoms are present, 
polysomnography is recommended (B++).
3.29.  Lipid and glucose metabolism should be monitored 
on a regular basis (Table 4) (B++).
3.30.  Blood pressure should be monitored regularly 
(Table 4) with an appropriately sized cuff. Patients 
with hypertension should be treated as clinically 
indicated (B++).
Management of ectopic ossifications
In PHP and related disorders, particularly POH, trig-
gering environmental factors for ectopic ossifications, 
such as trauma, infection and/or metabolic or immune 
abnormalities, have not been systematically studied240; 
however, clinical experience strongly suggests that 
these factors do not contribute to new ossifications. By 
contrast, in FOP, another disease featuring ectopic bone 
formation, external factors, such as trauma or infec-
tions, are well- known triggering events contributing to 
new bone formation or worsening of existing ones10.
A systematic literature search led to the following 
observations. First, no external factor has been shown 
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to induce the development of ectopic ossifications in 
patients with PHP1A, PPHP or POH. Second, no cor-
relation exists between PTH levels or serum levels of 
calcium–phosphorus and the occurrence of ectopic ossi-
fications. Third, ectopic ossifications often occur in loca-
tions subjected to high pressure loads, such as the heel81. 
Fourth, plate- like or severe ossifications might develop 
within the first year of life and progressively invade the 
deep tissues58. Finally, paternally inherited mutations 
at GNAS, mainly those leading to a truncated protein, 
have been reported as contributing to the development 
of ectopic ossifications41,145.
As a result of the rareness of these conditions, limited 
information is available about prognosis. Currently, no 
effective treatments exist for the management or pre-
vention of ectopic ossifications. Surgical removal of the 
ectopic ossifications can be performed when the lesions 
are well delimited. This is rarely the case in patients 
with POH, but it can be effective in those with osteoma 
cutis and in superficial lesions associated with PPHP 
or PHP1A with successful long- term results58,59,81,241. In 
most cases, surgical resection is followed by recurrence 
or complications3,83,242–245. Successful functional reposi-
tioning of a joint after the development of a contracture 
due to ectopic ossifications was reported in one child243. 
Amputations are sometimes needed in the setting of 
severe growth retardation and functional ankyloses83 or 
following the  development of severe  infections in recur-
rent skin ulcerations242.
Bisphosphonates have been proposed to prevent the 
post- surgical complications and recurrences of ossifi-
cations owing to their known effect on inhibiting bone 
turnover. Although we are lacking data from controlled 
trials, in five patients with neurogenic or post- traumatic 
ectopic ossifications, pamidronate seemed to prevent 
recurrences79. Pamidronate has also been used in a single 
patient with POH as a primary treatment of progressing 
heterotopic ossifications, with an apparent delay in new 
bone formation, rather than a change in the ectopic bone 
itself246. Etidronate has also been used with an apparent 
beneficial effect on the progression of ectopic ossifica-
tions in one patient with a POH- like presentation247, but 
no improvement was reported in another patient with 
POH248. Finally, topical sodium thiosulfate has been 
successfully administered in patients with hyperphos-
phataemic familial tumoural calcinosis or those with 
hyperphosphataemia–hyperostosis syndrome with a 
clinically and radiologically significant decrease of ectopic 
ossifications249. Preliminary data indicate that bisphospho-
nates might also delay the progression of ectopic ossifica-
tions in patients with ossifications secondary to PHP or 
related disorders250. Physical therapy and meticulous skin 
care remain the most important conservative approaches 
to preserve movement and to prevent cutaneous 
breakdown, respectively251,252.
Recommendations
3.31.  The presence of cutaneous bony plaques should 
be investigated by careful examination at each 
visit in all patients with GNAS mutations, espe-
cially those with mutations on the paternal allele 
(POH and PPHP). Patients and families should be 
instructed about self- examination. We recommend 
documenting the following at each visit: location 
and size of ossifications; involvement of joints 
and impairment of movement and bone growth; 
predilection of lesions towards areas exposed to 
increased pressure due to weight bearing (feet and 
ankles); assessment of triggering events (trauma, 
infection, inflammation and surgery); association 
with pubertal development; and treatment with 
rhGH (A++).
3.32.  Regular imaging of ectopic ossifications is not 
indicated (A++).
3.33.  Imaging of ossifications should be performed 
using CT or MRI, depending on localization, 
when the lesions are painful, symptomatic, jeop-
ardize joint or organ function or are being consid-
ered for surgical excision (A++).
3.34.  When the diagnosis underlying ectopic ossifica-
tions is doubtful and when FOP has been excluded, 
there is no contraindication to perform a biopsy 
of the lesion, as no evidence suggests that inflam-
mation or trauma leads to progression of ectopic 
ossifications in PHP and related disorders (B++).
3.35.  Physical therapy and meticulous skin care are the 
most important approaches for the prevention of 
development and/or progression of ectopic ossifi-
cations. Surgical excision should be considered in 
the presence of delimited, superficial lesions asso-
ciated with pain and/or movement impairment. 
The patient should be referred to a surgeon with 
experience in the management of ectopic ossifi-
cations. In extensive ossifications around a joint, 
avoid immobilization (through casts), as this might 
lead to ankyloses of the joint (B+).
3.36.  There is no evidence for recommending the use of 
nonsteroidal anti- inflammatory drugs, bisphos-
phonates or steroids in primary or peri- surgical 
treatment of asymptomatic ectopic ossifications (B+).
Brachydactyly and orthopaedic issues
Skeletal complications. Brachydactyly might contribute 
to difficulty with fine motor skills, such as handwriting, 
in children with PHP1A, leading to the need for occu-
pational therapy services in early childhood253. A high 
incidence of carpal tunnel syndrome has been observed 
in patients with PHP1A and PPHP (67% of patients with 
PHP1A reported symptoms versus 15% of the general 
population)253.
Additional skeletal features have been described in 
different disorders of the PTH–PTHrP pathway, such as 
Madelung deformity72,128, spinal stenosis203,254–257, acro- 
osteolysis, cortical irregularity of long bones and metadi-
aphyseal enchondromata or short humerus and curved 
radius258, as well as other craniofacial peculiarities (typi-
cal pear- shaped nose, long and flat philtrum, thin upper 
lip and receding chin) and phalangeal cone- shaped 
epiphyses, resulting in clinodactyly259. Depending on 
the functional consequences, the patient might require 
corrective orthopaedic surgery.
Finally, many paediatric patients have a history of 
recurrent otitis media requiring a tympanostomy tube 
or tympanoplasty230.
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Oral complications. Several oral manifestations have 
been described in patients with PHP and related dis-
orders, including aplasia, thin enamel with enlarged 
pulp chamber, hypoplasia, hypodontia, pulp calcifica-
tion, multiple carious teeth, multiple unerupted teeth or 
delayed tooth eruption, crowded anterior teeth, anterior 
open bite, gingival hyperplasia, gingivitis with spontane-
ous bleeding and pain88,260. Familial nonsyndromic pri-
mary failure of tooth eruption has also been described 
in patients with mutations in PTHR1 and PTHrP88,261.
Recommendations
3.37.  In addition to their use for diagnosis and character-
ization of brachydactyly, further specific radiolog-
ical investigations should be reserved for patients 
with specific clinical suspicion of orthopaedic mal-
formation or functional impairment, particularly 
in the presence of neurological signs or symptoms. 
Patients with severe brachydactyly should receive 
formal evaluation of their fine motor skills as 
well as be supplied with appropriate orthopaedic 
devices when indicated (that is, special shoes and 
orthopaedic insoles) (A++).
3.38.  Specific multidisciplinary evaluation and therapy 
should be offered for rare orthopaedic or neuro-
logical manifestations: spinal stenosis, bilateral 
slipped capital femoral epiphyses, temporoman-
dibular joint ankyloses, precocious scoliosis, Chiari 
malformation type 1 and cranial synostosis (A++).
Management of cognitive function
Patients with PHP1A present with psychomotor and 
cognitive abnormalities, which are defined as a history 
of developmental delay and learning disability, with 
reduced performance on the Wechsler intelligence 
scale24,42,262 and an increased incidence of psychiatric 
manifestations that might be the consequence of the 
disease or of long- term hypocalcaemia42,207.
In general, global retardation of developmental mile-
stones, psychomotor retardation, delayed speech or the 
need for an assistant teacher and extra school help are 
reported18,263,264. The performance IQ is more affected 
than the verbal IQ24. Intellectual disability seems to be 
more prevalent in patients with PHP1A than in patients 
with PPHP, which suggests that Gsα is imprinted in the 
brain24,214,229. The existence of neurological manifesta-
tions or true neuropsychiatric phenotype due to organic 
CNS alterations, and specifically Chiari malformation 
type 1, should be considered38,207,265. Finally, the preva-
lence and severity of cognitive impairment and develop-
mental delay vary among patients with acrodysostosis, 
but a detailed clinical description is lacking5,6,14,63,266.
Recommendation
3.39.  Consider referral to a neuropsychologist for neuro-
cognitive and/or behavioural assessment at diagno-
sis or at preschool age, particularly in patients with 
PHP1A and acrodysostosis due to PDE4D muta-
tions, and also if otherwise appropriate (for instance, 
if the patient presents with symptoms of cognitive 
impairment). Additional testing and support as 
required should also be considered (A++).
Malignancy risk
Three case reports have described the coexistence of 
PHP or a related disorder with malignancy: PHP1A and 
cerebellar pilocytic astrocytoma267, PHP1B and osteo-
sarcoma168 and POH with medulloblastoma82. However, 
large- scale studies aimed at determining tumour risk in 
PHP and related disorders have not been carried out. A 
Danish study has investigated all patients with a diagnosis 
of PHP or a related disorder (clinical and/or genetically 
confirmed) to determine their mortality data and risk 
of complications using data from the Danish National 
Patient Registry8. With a total of 60 cases, patients with 
PHP or a related disorder were found to have an increased 
risk of neuropsychiatric disorders, infections, seizures and 
cataracts, whereas their risk of renal, cardiovascular 
and malignant disorders and fractures was similar to that 
of the general background population. The same results 
Box 1 | Future research directions
Diagnosis and natural history of the disorders
•	extensive and systematic data on the following:
 - Growth pattern and final heights
 - Bone maturation and timing of premature closure of the epiphysis
 - Pubertal development and gonadal function (including menopause), fertility and 
mineralization status
 - metabolic alterations and blood pressure
 - objective evaluation by standardized tests for cognitive and psychomotor 
impairment
•	Identification of factors that contribute to the development and progression of ectopic 
bone formation
•	Pursuit of initiatives for the development of a novel diagnostic classification
Molecular diagnosis
•	Frequency and associated phenotypes of the different molecular alterations
•	Development of testing methodology and validation of technologies for the 
detection of partial methylation defects
•	Prevalence of multilocus imprinting disturbance (mlID) and its effect on the phenotype
•	Identification of the prevalence and effects of genetic variants underlying 
methylation defects (affecting GNAS alone or mlID)
•	Identification of the prevalence of molecular defects at the parathyroid hormone (PTH)–
parathyroid hormone- related protein (PTHrP) signalling cascade in a mosaic state
•	Identification of new genes involved in the PTH–PTHrP signalling cascade and their 
association with as- yet-unresolved cases with PHP and related disorders
•	Identification of the receptor pathway upstream of GNAS that is associated with the 
development of ectopic ossification
Follow- up and management
•	optimal calcium, phosphorus and PTH levels during active treatment for PTH resistance
•	Complications related to chronic hypocalcaemia, long- term PTH elevation and their 
treatment
•	Indications, doses, efficacy and optimal timing for recombinant human growth 
hormone (rhGH) use and indication for puberty blockers
•	Contribution of reduced energy expenditure, decreased lipolysis, growth hormone- 
releasing hormone (GHRH) resistance and hyperphagia to the onset and degree of 
obesity
•	Preclinical and clinical trials to investigate the benefit of post- surgical 
bisphosphonates and of other candidate drugs (inhibitors of the Hedgehog signalling 
pathway and retinoic acid receptor- γ agonists)
•	Quality of life (Qol): both systematic evaluation with validated Qol questionnaires 
(that is, the 36-item Short Form Survey (SF-36)) and validation of disease- specific 
questionnaires are needed
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were obtained when analysing only the subgroup with 
genetically verified PHP or a related disorder.
An increased tumour risk might be hypothesized 
to exist in patients with PHP1B and MLID, mostly 
patients with MLID that are associated with Beckwith–
Wiedemann syndrome, a growth disorder characterized 
by embryonal tumours. However, the few data collected 
to date did not report any tumours in patients with 
PHP1B and MLID92,104.
Recommendation
3.40.  There are no data to recommend a specific screen-
ing for malignancies in PHP and related disorders 
(A+++).
Conclusions
Patients with PHP and related disorders face a wide range 
of problems from early childhood to adulthood. These 
include potentially severe alterations in mineral metab-
olism, which could be associated with seizures, other 
endocrine deficiencies due to hormone resistance that 
lead to hypothyroidism, hypogonadism and GH defi-
ciency, growth impairment independently of hormonal 
status, ectopic ossifications with potential severe limita-
tion of mobility, skeletal issues and cognitive and psych-
omotor impairment. This highly heterogeneous clinical 
picture renders a multidisciplinary approach mandatory 
in these disorders, as very specialized expertise is required 
to manage each of the many clinical aspects and potential 
complications of PHP and related disorders.
In addition, this group of disorders is caused by dif-
ferent and complex genetic and epigenetic defects, such 
that establishing a correct molecular diagnosis might 
be difficult and time consuming for both patients and 
their families and physicians. There is an urgent need to 
gather forces and cohorts of patients to implement regis-
tries, to improve knowledge on the natural history of the 
diseases, to better understand the bridges between these 
clinically heterogeneous but still closely related diseases 
and, moreover, to develop new therapies.
This article, which is based on published evidence 
and expert opinion, is the first international consensus 
statement for the diagnosis and management of PHP 
and related disorders. The 67 recommendations apply 
to all patients with a clinical diagnosis, independently of 
molecular confirmation. Nevertheless, in some patients, 
the identification of the underlying genetic or epigenetic 
defect might help clinicians to look for specific clinical 
manifestations with consequent appropriate manage-
ment. A multidisciplinary approach is needed in most 
cases, and Table 4 summarizes the main interventions 
as well as their timing.
Given the lack of strong evidence- based data, 
particularly for management of these patients, 
international collaboration and long- term clinical 
trials looking at the natural history, the diseases’ clas-
sification and the outcome of treatments are urgently 
needed (box 1).
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